You are here

Aduhelm

Biogen's Aduhelm headache returns as appeals court revives part of investor lawsuit

Biogen's Aduhelm headache returns as appeals court revives part of investor lawsuit

Fierce Pharma

Alzheimer's disease

Flag link:

6 Drugs Approved Despite Failed Trials or Minimal Data

6 Drugs Approved Despite Failed Trials or Minimal Data

BioSpace

Sarepta Therapeutics

Flag link:

After quitting FDA adcomm in protest of Aduhelm decision, Harvard's Aaron Kesselheim finds agency has an approval bias

After quitting FDA adcomm in protest of Aduhelm decision, Harvard's Aaron Kesselheim finds agency has an approval bias

Fierce Pharma

Alzheimer's disease

advisory committees

Flag link:

Massachusetts judge dismisses lawsuit against Biogen over failed launch of Alzheimer's drug Aduhelm

Massachusetts judge dismisses lawsuit against Biogen over failed launch of Alzheimer's drug Aduhelm

Endpoints

Flag link:

Biogen's head of neurodegeneration leaves

Biogen's head of neurodegeneration leaves

Fierce Biotech

women executives

Alzheimer's disease

Flag link:

VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm

VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm

Endpoints

Alzheimer's disease

Flag link:

Despite recent approvals, significant unmet need remains in Alzheimer’s market

Despite recent approvals, significant unmet need remains in Alzheimer’s market

Clinical Trials Arena

Alzheimer's disease

Avanir Pharmaceuticals

Flag link:

Billy Dunn, FDA’s top neuroscience official to depart agency

Billy Dunn, FDA’s top neuroscience official to depart agency

RAPS.org

Flag link:

FDA adds warning of 'larger areas of bleeding' in brain to Biogen's Aduhelm label

FDA adds warning of 'larger areas of bleeding' in brain to Biogen's Aduhelm label

Endpoints

Alzheimer's disease

Flag link:

Eisai learns from Biogen’s Aduhelm disaster

Eisai learns from Biogen’s Aduhelm disaster

EP Vantage

Alzheimer's disease

Flag link:

Biogen, FDA's inappropriate Aduhelm coordination detailed in blistering congressional report

Biogen, FDA's inappropriate Aduhelm coordination detailed in blistering congressional report

Fierce Pharma

Alzheimer's disease

Flag link:

Lilly’s Donanemab Shines vs. Aduhelm in First Active Comparator Study

Lilly’s Donanemab Shines vs. Aduhelm in First Active Comparator Study

BioSpace

clinical trials

Alzheimer's disease

Flag link:

Where Will Biogen Be in 5 Years?

Where Will Biogen Be in 5 Years?

Motley Fool

Alzheimer's disease

Flag link:

Medicare Part B premiums to drop 3% next year, partly due to limited Aduhelm coverage

Medicare Part B premiums to drop 3% next year, partly due to limited Aduhelm coverage

Medical Marketing and Media

Medicare Part B

Flag link:

Biogen nets $592M in Boston real estate sale as cost-cutting campaign rolls on

Biogen nets $592M in Boston real estate sale as cost-cutting campaign rolls on

Fierce Pharma

Flag link:

Aduhelm’s loss is a win for value-based drug pricing

Aduhelm’s loss is a win for value-based drug pricing

MedCity News

value-based pricing

Alzheimer's disease

Flag link:

Biogen deflects claims it misled shareholders about Aduhelm's success

Biogen deflects claims it misled shareholders about Aduhelm's success

Fierce Pharma

Alzheimer's disease

Flag link:

Roche, Biogen temper Alzheimer’s expectations in Q2 calls. Will Lilly follow suit in August?

Roche, Biogen temper Alzheimer’s expectations in Q2 calls. Will Lilly follow suit in August?

Fierce Biotech

Alzheimer's disease

Flag link:

For accounting purposes, Biogen says its $223M inventory of Aduhelm is basically worthless

For accounting purposes, Biogen says its $223M inventory of Aduhelm is basically worthless

Endpoints

Alzheimer's disease

Flag link:

Biogen, targeting $1B in savings, employs 300 fewer staffers in Massachusetts than it did in September: report

Biogen, targeting $1B in savings, employs 300 fewer staffers in Massachusetts than it did in September: report

Fierce Biotech

Flag link:

Pages